03/14/23 7:00 AMNasdaq : AVIR covid-19New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral ResearchLow risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS -CoV-2 variants of concern evaluated as well as other human coronaviruses such as HCoV-229E, HCoV-OC43, and SARS-CoV-1 FavorableRHEA-AIneutral
03/08/23 7:00 AMNasdaq : AVIR covid-19New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral ResearchAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentations at the 36 thRHEA-AIneutral
02/28/23 4:05 PMNasdaq : AVIR earningsAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatePhase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23 Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV to start enrollment in 2Q23; initial results expected byRHEA-AIneutral
02/23/23 7:00 AMNasdaq : AVIR clinical trialAtea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that data from three Phase 1 studiesRHEA-AIneutral
02/21/23 7:00 AMNasdaq : AVIR conferencesearningsAtea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, February 28, 2023, at 4:30 p.m. ET to report financial results for theRHEA-AIneutral
02/15/23 4:05 PMNasdaq : AVIR conferencesAtea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic InfectionsAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22,RHEA-AIneutral
02/07/23 7:00 AMNasdaq : AVIR conferencesAtea Pharmaceuticals to Present at the SVB Securities Global Biopharma ConferenceAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, willRHEA-AIneutral
01/09/23 7:00 AMNasdaq : AVIR Atea Pharmaceuticals Highlights Strategic Priorities for 2023Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 CombinationRHEA-AIneutral
01/04/23 7:00 AMNasdaq : AVIR conferencesAtea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the 41 stRHEA-AIneutral
11/29/22 7:00 AMNasdaq : AVIR clinical trialcovid-19Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of Bemnifosbuvir Supported by Clinical Data from Late-Stage MORNINGSKY Trial and Prior StudiesRHEA-AIneutral